Monday, April 8, 2013

Pope invites Romans to join him at city basilica

VATICAN CITY (AP) ? Pope Francis is inviting people to join him in Mass at Rome's main church, St. John in Lateran Basilica.

Pontiffs are also the bishop of Rome, and the gathering Sunday evening reminds Romans of this pastoral role.

Before entering the basilica, Francis attends a ceremony to unveil a plaque renaming St. John in Lateran Square after Pope John Paul II. The late pontiff enthusiastically embraced his role as Rome's bishop, visiting hundreds of city parishes. The vast piazza is a popular venue for free rock concerts and rallies by union leaders and politicians.

Francis issued the invite during his noon appearance and blessing from a window of the Vatican's Apostolic Palace overlooking St. Peter's Square, where tens of thousands of pilgrims and tourists came to cheer him.

Source: http://news.yahoo.com/pope-invites-romans-join-him-city-basilica-111300001.html

hanukkah justin tv justin tv Sarah Savage Jaimie Alexander Army Navy Game john lennon

Do I Ever Need to Upgrade My Cable Modem?

Do I Ever Need to Upgrade My Cable Modem? Dear Lifehacker,
I haven't moved in several years, and I'm still using the cable modem that I purchased and installed when I moved in here. It's pretty old and busted, but it works. Still, I wonder: should I upgrade it? Are there any benefits to newer modems that older modems don't have? Will it make my connection faster?

Sincerely,
Need for Speed

Dear Need for Speed,
Depending on how long "several years" is exactly, there could be really good reason to upgrade your modem, or no reason at all. Still, the quick answer is that yes, there are some differences between older modems and newer ones that might make you consider upgrading?but you have to do your homework first. Here's how.

If You Rent Your Modem, You Should Probably At Least Buy Your Own

Do I Ever Need to Upgrade My Cable Modem? If you're currently renting your modem from your Internet Service Provider (ISP), you're probably paying a small fee for the privilege (at least here in the United States.) Check your bill. It's usually only a few dollars per month, but that can add up quickly. Do the math: if you plan to live in the same place or have the same ISP for longer than a couple of years, you're better off just buying your own cable modem and using that, instead of paying your ISP a monthly fee to rent one. Photo by Luis Ventura.

There's something to the argument that renting a cable modem lets you call your ISP at any time and ask for a new one that supports newer networking technologies (and potentially faster connection speeds), but don't worry much about that. ISPs don't update their networks so frequently that you'd benefit from a new cable modem more often than it would make sense to buy one. Plus, even if you called your ISP and asked for a new modem, there's no guarantee they'd give you a better one, or even give you a new one at all. They'd probably charge you for the replacement. Remember, we think it's rarely a good idea to rent a cable modem, and if you do opt to buy one, we have a great recommendation for you.

Does Your Modem Support Your ISP's Latest Networking Technology?

Do I Ever Need to Upgrade My Cable Modem? The next major question you should ask, even if you own your cable modem, is whether your ISP's network technology has surpassed it. Lets say you bought your cable modem way back in 2005, and you've been using it at different homes with the same cable company ever since. Sure, it works, but odds are your cable company has upgraded their network since then, and your modem may not be capable of taking advantage of the speed available to you. Photo by Bryan Brenneman.

DOCSIS (short for Data Over Cable Service Interface Specification) is an international data transmission standard for use with cable networks. You may have heard the term when most major cable companies were making the uplift from DOCSIS 2.0 to DOCSIS 3.0, back around 2010 and 2011. Most cable companies?especially in urban and suburban areas?have already made the switch. Others in more rural regions are still working on it, or haven't made the change at all. Check with your cable company and see if they're made the switch. Then, Google the model number of your current cable modem and see if it's a DOCSIS 3.0 modem. If it is, you're good to go and you don't need to upgrade.

If your modem isn't a DOCSIS 3.0 modem, it's time to go shopping. Most providers have preferred models that they've tested and recommend you use. Check your ISP's compatible device list (here's Comcast's, Time Warner's, Cox's, and ATT's, for example) for leads on what you should buy. If you still have an old DOCSIS 2.0 modem and there's a firmware upgrade for it, you may be able to extend its life a bit and even see a speed boost in the process. If you're somehow still rocking an old DOCSIS 1.1 modem, your best bet would be to upgrade if you want the added speed and features available to you. It's the only way you'll ever see some of those super-fast download speeds your ISP claims to deliver.

Weigh the Pros and Cons

Do I Ever Need to Upgrade My Cable Modem? Now that we've tackled the two biggest questions you should answer before you think about upgrading your cable modem, let's look at the pros and cons:

Pros:

  • A newer, DOCSIS 3.0 modem can, if your ISP supports it, offer a significant performance boost over older modems on any plan (except low-end, low-speed tiers). Photo by Kevin Jarrett.
  • If you have a high-speed plan with your ISP, moving up from a 2.0 modem means you'll be able to reach higher download and upload speeds (in bursts, anyway) than you would with an older device.
  • Buying your own modem?especially a newer one?makes you portable to any cable provider you have available to you, and lets you use the latest available technology on any of them.
  • Owning your own cable modem allows you to log in and manage it, and observe whether issues with your connection are due to connectivity or power problems upstream. You can even diagnose your ISP's issues and report them when you call for support.
  • If your ISP hasn't upgraded to DOCSIS 3.0 yet, upgrading to a 3.0 modem will futureproof you for the eventual transition, even if it doesn't translate to a significant performance increase yet.

Cons:

Do I Ever Need to Upgrade My Cable Modem?

  • All of these pros and benefits only really apply if you haven't upgraded in a long time, and only if your current modem isn't already a DOCSIS 3.0 model.
  • If you have a low-speed, entry-level plan with your ISP, your speed cap may be low enough that you won't notice the difference with a new modem at all. Those low-speed plans aren't as widely available as they used to be, but it's something to consider if your access plan boasts a 5Mb/s download speed cap.
  • If you're happy with your current setup, and don't really see a need to improve it, the performance boosts may not be worth the cash to you, especially considering some of the best cable modems can run around $100, and our favorite model (and The Wirecutter's favorite) is just shy of $85 at Amazon.
  • Depending on your ISP, they may be willing to upgrade your modem for you?without you having to buy one yourself. You still have to contend with the rental fee, but for some of you, it might make sense to do so.

If you're still on the fence, call your cable provider and ask. They should be able to tell you whether your current cable modem is worth upgrading (and they'll even offer to lease you a replacement).. If they can't tell you (or if you, like me, have no faith at all in your ISP's phone support to answer a simple question) just Google your model and see how old it is, whether the manufacturer is still making it (or even supporting it), and what people are saying about it. You should be able to tell if it's so old no one's making it or talking about it anymore. If everything you read is people upgrading from your model, it's time to do the same.

Good luck,
Lifehacker

Have a question or suggestion for Ask Lifehacker? Send it to tips+asklh@lifehacker.com.

Source: http://feeds.gawker.com/~r/lifehacker/full/~3/FsWY_cY4tgQ/do-i-ever-need-to-upgrade-my-cable-modem

mediterranean diet chase kim kardashian pregnant papa johns dominos dominos Perez Hilton

Engineered T cells kill tumors but spare normal tissue in an animal model

Engineered T cells kill tumors but spare normal tissue in an animal model [ Back to EurekAlert! ] Public release date: 7-Apr-2013
[ | E-mail | Share Share ]

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-459-0544
University of Pennsylvania School of Medicine

PHILADELPHIA The need to distinguish between normal cells and tumor cells is a feature that has been long sought for most types of cancer drugs. Tumor antigens, unique proteins on the surface of a tumor, are potential targets for a normal immune response against cancer. Identifying which antigens a patient's tumor cells express is the cornerstone of designing cancer therapy for that individual. But some of these tumor antigens are also expressed on normal cells, inching personalized therapy back to the original problem.

T cells made to express a protein called CAR, for chimeric antigen receptor, are engineered by grafting a portion of a tumor-specific antibody onto an immune cell, allowing them to recognize antigens on the cell surface. Early first-generation CARs had one signaling domain for T-cell activation. Second-generation CARs are more commonly used and have two signaling domains within the immune cell, one for T-cell activation and another for T- cell costimulation to boost the T cell's function.

Importantly, CARs allow patients' T cells to recognize tumor antigens and kill certain tumor cells. A large number of tumor-specific, cancer-fighting CAR T cells can be generated in a specialized lab using patients' own T cells, which are then infused back into them for therapy. Despite promising clinical results, it is now recognized that some CAR-based therapies may involve toxicity against normal tissues that express low amounts of the targeted tumor-associated antigen.

To address this issue, Daniel J. Powell Jr., PhD, research assistant professor of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, and director of the Cellular Therapy Tissue Facility, developed an innovative dual CAR approach in which the activation signal for T cells is physically dissociated from a second costimulatory signal for immune cells. The two CARs carry different antigen specificity -- mesothelin and a-folate receptor. Mesothelin is primarily associated with mesothelioma and ovarian cancer, and a-folate receptor with ovarian cancer.

Powell likens this dual CAR approach to having two different gas pedals, one for starting the immune system and a second for revving it up. Dual CAR T cells are more selective for tumor cells since their full activity requires interaction with both antigens, which are only co-expressed on tumor cells, not normal tissue.

Dual CAR T cells showed weak cytokine production against target cells expressing only one tumor-associated antigen in lab assays, similar to first-generation CAR T cells bearing the CD3 activation domain only, but demonstrated enhanced cytokine production upon encountering natural or engineered tumor cells expressing both antigens, equivalent to second-generation CAR T cells with dual, but unseparated signaling.

In a mouse model of human ovarian cancer, T cells with the dual-signaling CARs persisted at high numbers in the blood, accumulated in tumors, and showed potent anti-cancer activity against human tumors. Dual CAR T cells were equivalent to second-generation CAR T cells in activity against tumors bearing two antigens. However, the dual-signaling CAR T cells did not react vigorously with normal tissue expressing one antigen while second- generation CAR T cells did.

"This new dual-specificity CAR approach can enhance the therapeutic efficacy of CAR T cells against cancer while minimizing reactivity against normal tissues," says Powell.

Their findings have been published in the inaugural issue of Cancer Immunology Research, the newest journal from the American Association for Cancer Research.

###

This work was supported by grants from the W.W. Smith Charitable Trust, the Sandy Rollman Ovarian Cancer Foundation, the Ovarian Cancer Research Fund (PPD-Penn-01.12), the National Cancer Institute (RO1-CA168900) and the Joint Fox Chase Cancer Center and University of Pennsylvania Ovarian Cancer SPORE (P50 CA083638).

Co-authors include Evripidis Lanitis, Mathilde Poussin, Alex W. Klattenhoff, Degang Song, and Carl H. June, all from Penn.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region. Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided $827 million to benefit our community.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Engineered T cells kill tumors but spare normal tissue in an animal model [ Back to EurekAlert! ] Public release date: 7-Apr-2013
[ | E-mail | Share Share ]

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-459-0544
University of Pennsylvania School of Medicine

PHILADELPHIA The need to distinguish between normal cells and tumor cells is a feature that has been long sought for most types of cancer drugs. Tumor antigens, unique proteins on the surface of a tumor, are potential targets for a normal immune response against cancer. Identifying which antigens a patient's tumor cells express is the cornerstone of designing cancer therapy for that individual. But some of these tumor antigens are also expressed on normal cells, inching personalized therapy back to the original problem.

T cells made to express a protein called CAR, for chimeric antigen receptor, are engineered by grafting a portion of a tumor-specific antibody onto an immune cell, allowing them to recognize antigens on the cell surface. Early first-generation CARs had one signaling domain for T-cell activation. Second-generation CARs are more commonly used and have two signaling domains within the immune cell, one for T-cell activation and another for T- cell costimulation to boost the T cell's function.

Importantly, CARs allow patients' T cells to recognize tumor antigens and kill certain tumor cells. A large number of tumor-specific, cancer-fighting CAR T cells can be generated in a specialized lab using patients' own T cells, which are then infused back into them for therapy. Despite promising clinical results, it is now recognized that some CAR-based therapies may involve toxicity against normal tissues that express low amounts of the targeted tumor-associated antigen.

To address this issue, Daniel J. Powell Jr., PhD, research assistant professor of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, and director of the Cellular Therapy Tissue Facility, developed an innovative dual CAR approach in which the activation signal for T cells is physically dissociated from a second costimulatory signal for immune cells. The two CARs carry different antigen specificity -- mesothelin and a-folate receptor. Mesothelin is primarily associated with mesothelioma and ovarian cancer, and a-folate receptor with ovarian cancer.

Powell likens this dual CAR approach to having two different gas pedals, one for starting the immune system and a second for revving it up. Dual CAR T cells are more selective for tumor cells since their full activity requires interaction with both antigens, which are only co-expressed on tumor cells, not normal tissue.

Dual CAR T cells showed weak cytokine production against target cells expressing only one tumor-associated antigen in lab assays, similar to first-generation CAR T cells bearing the CD3 activation domain only, but demonstrated enhanced cytokine production upon encountering natural or engineered tumor cells expressing both antigens, equivalent to second-generation CAR T cells with dual, but unseparated signaling.

In a mouse model of human ovarian cancer, T cells with the dual-signaling CARs persisted at high numbers in the blood, accumulated in tumors, and showed potent anti-cancer activity against human tumors. Dual CAR T cells were equivalent to second-generation CAR T cells in activity against tumors bearing two antigens. However, the dual-signaling CAR T cells did not react vigorously with normal tissue expressing one antigen while second- generation CAR T cells did.

"This new dual-specificity CAR approach can enhance the therapeutic efficacy of CAR T cells against cancer while minimizing reactivity against normal tissues," says Powell.

Their findings have been published in the inaugural issue of Cancer Immunology Research, the newest journal from the American Association for Cancer Research.

###

This work was supported by grants from the W.W. Smith Charitable Trust, the Sandy Rollman Ovarian Cancer Foundation, the Ovarian Cancer Research Fund (PPD-Penn-01.12), the National Cancer Institute (RO1-CA168900) and the Joint Fox Chase Cancer Center and University of Pennsylvania Ovarian Cancer SPORE (P50 CA083638).

Co-authors include Evripidis Lanitis, Mathilde Poussin, Alex W. Klattenhoff, Degang Song, and Carl H. June, all from Penn.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region. Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided $827 million to benefit our community.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2013-04/uops-etc040213.php

alex o loughlin the godfather cape breton bowling green marysville tornados dr. seuss

Facebook Home en Chat Heads gepresenteerd voor Android

Facebook Home en Chat Heads gepresenteerd voor Android
Facebook heeft twee nieuwe diensten ge?ntroduceerd voor Android. Met Facebook Home en Chat Heads wil het sociale medium de Facebook-integratie op het Android-platform flink verbeteren.

Read the full article on?PC-Active??


Source: http://feedproxy.google.com/~r/feedjunknl/~3/d1EvrjjUrto/Facebook%20Home%20en%20Chat%20Heads%20gepresenteerd%20voor%20Android

dantoni gillian anderson leah remini black and tan dwight howard trade ncaa bracket 2012 kyle orton

Saturday, April 6, 2013

Samsung Galaxy Note 8 arrives at one UK store: ?339 for the WiFi-only, 16GB model

Samsung Galaxy Note 8.0 arrives at one UK store: ?339 for the WiFi-only, 16GB model

Have you been feeling a bit like a UK-based Goldilocks? The Galaxy Note II's too small, the Note 10.1 a trifle too big, but the Note 8 looks just right? Well, today's your lucky day, as the mid-sized tablet has officially launched in the Queen's dominion. The WiFi-only, 16GB model will set you back £339 (approximately $516), and at the moment, you'll only find it at the Samsung Experience Store in Westfield Stratford City. It'll be available elsewhere shortly, and it's probably worth waiting -- from April 15th for a limited time, buyers will get a few extras: a £20 voucher for the Samsung Learning Hub, a two-month subscription to The Times, free access to the Samsung Music Hub for a month, and a couple of games and AVG Anti-Virus Pro gratis. If tethering ain't your bag but you need data on the go, a gent from the Westfield store told us the 3G version is on its way, but couldn't give us a firm arrival date. It's our duty to warn you Westfield is a crowded nightmare at the best of times, and the arrival of a new Samsung tablet ain't gonna help that.

Filed under: ,

Comments

Source: http://feeds.engadget.com/~r/weblogsinc/engadget/~3/G-1RLYTf5A8/

jacoby ellsbury lionel richie kenny rogers avatar the last airbender david wright cory booker cubs

Obama, Israel and the "Jewish Lobby" /Talia Katz

Apr 4 2013
Barack Obama's first visit to Israel as President last month has been widely analysed in the context of the Israel-Palestinian peace process and in terms of other regional security concerns, with a particular focus on the sometimes rocky relationship he shares with Israeli PM Benyamin Netanyahu. However, both Obama and some of Australia's less-informed commentators chose to emphasise what the visit tells us about the overall Israel-US relationship, above and beyond any personal issues between individuals.

Obama's address to an audience of 600 students in Jerusalem on March 21 made it clear that the connection between Israel and the US goes far beyond democratic, security or economic interests and pre-dates the current political leadership, back to the creation of the State.

"Those ties began only 11 minutes after Israeli independence, when the United States was the first nation to recognize the State of Israel. As President Truman said in explaining his decision to recognize Israel, he said, "I believe it has a glorious future before it not just as another sovereign nation, but as an embodiment of the great ideals of our civilization." And since then, we've built a friendship that advances our shared interests," he said.

In his wide-ranging speech, which was well received by both commentators and the students who attended, Obama went into detail about the US/Israel alliance:

But the source of our friendship extends beyond mere interests, just as it has transcended political parties and individual leaders. America is a nation of immigrants. America is strengthened by diversity. America is enriched by faith. We are governed not simply by men and women, but by laws. We're fueled by entrepreneurship and innovation, and we are defined by a democratic discourse that allows each generation to reimagine and renew our union once more. So in Israel, we see values that we share, even as we recognize what makes us different. That is an essential part of our bond.

But despite the President's eloquence, some media commentators and pundits outdid themselves in attempting to use the visit to push the ugly but increasing well-worn argument that it is only because of the undue and often insidious impact of the "Israel Lobby" (or more crudely the "Jewish Lobby") that the US has the policy positions that it does on Israel, and the US-Israel alliance endures. Some go as far as to suggest that Israel somehow has direct control over the American government.

Paul McGeough, for example, in his March 17 Canberra Times article covering Obama's first visit to Israel simply assumed that the US was stupidly failing to follow its own interests by not ditching Israel and ending all aid. Instead, he presented a diatribe about the "Pussyfoot President", who he classed as "manager-in-chief of the Israeli Occupation" and "passive aggressive." McGeough implied the President was weak and subservient to Israel in failing to end the "madness" of US support.

Bizarrely, according to McGeough's warped sensibilities, joint Israel-US investment in an air force security facility was nothing more than a ruse to deny beleaguered Palestinians working permits on the secure site.

It's part of a deal in the so called peace process, by which Israel got about $500 million for new bases to make up for those it would give up in the Occupied Territories. Nice, eh? They're still occupying; Washington's still paying.

To keep writing blank cheques on a cash-strapped US Treasury to cover ballooning costs, and at the same time do nothing to bring about, or impose, a peace that might reduce that cost is, well, it's madness.

His thesis, that the US is unable to extricate itself from its "mad" relationship with Israel, seemed utterly ignorant and uninterested in the shared interests, ideas, innovations and industries that Israel and the US enjoy (for more on this see my previous post on the subject of the shared interests underpinning the US-Israel partnership.)

Similarly, Michael Brissendon's reportage for the ABC during the 2012 US Presidential election campaign presented Israel's foreign policy interests, and the lobby that represents them in Washington, as the fulcrum upon which the election hinged.

Brissendon began his 7.30 news story on March 21 with news of Iran's rapid movement towards weapons grade fuel production and the increasing calls for a military strike. He then moved on to suggest that Israel and "the most powerful Jewish lobby group in the United States: the American-Israel Public Affairs Committee" was the cause for the increasingly enthusiastic "chest thumping" about Iran, saying "the factors driving the hawkish rhetoric have as much to do with the politics in Washington as anything else."

In this country the depth of a presidential candidate's support for Israel is often seen as a guide to their overall policy strength. But some have interpreted support for Israel as support for AIPAC, even if strangely enough sometimes the policy positions are at odds with the vast majority of American Jewish voters.

Interviewed by Annabelle Quince for ABC Radio National "Rear View" program in March 2012, US academic and "Israel Lobby" conspiracy theorist John Mearsheimer also made the case that the Israel Lobby (Mearsheimer is careful to avoid the crude "Jewish Lobby" language of Brissendon) drives US foreign policy towards a pro-Israel stance via money, as well as votes and control over the media.

[To] be even more specific, a lot of the lobby's power comes from money. Everybody in this country who runs for congress or runs for the president understands full well that it would be a huge mistake to cross the lobby, because not only would you not get any money from organisations in the lobby, but your opponent would get lots of money, and that would not be good. So money is a very important source of power.

Votes also matter. American Jews are probably about two per cent of the population, but their turnout on Election Day is very high and they're located in a number of very important states. Just take Florida, for example. In the 2000 presidential election, it all came down to a handful of votes in Florida. Well, Florida has a large number of Jews ...

It's also important to recognise that supporters of Israel have great influence in the American media: The Wall Street Journal, Fox News, The Washington Post, these are media outlets that are effectively in a position where they defend Israel at almost every turn. And that coupled with all those factors allows the lobby to be very powerful."

Likewise, several letters to the editor by Chris Williams, published in the Canberra Times, have presented theories about a Mossad controlled US government, about infiltration by Israeli intelligence officers into high ranking positions in the US and Australian governments, and general conspiracy related to foreign policy decision making.

This individual, and anyone who thinks like him or feels he may have a point, needs to read the recent discussion of the American "Israel Lobby" by top American writer, academic and pundit on US foreign policy Walter Russell Mead.

Mead accurately describes where these people are coming from according to a mindset he encountered in many of the countries to which he travels:

Why, people ask, does the United States incur such risks and costs for the sake of this small country? Why does the United States direct so much foreign aid to it? Why does the United States take its part at the United Nations at such diplomatic cost?

The answer most people around the world give is a very simple one: America takes the positions it takes on Israel because of the power of "the Jews." By their campaign contributions, by their (alleged) control of the media, by their (alleged) single-minded focus on Israeli interests, America's supposedly well-organized, well-funded, and very determined Jews succeed in controlling American opinion and American policy. The Jewish tail wags the American dog.

In much of the world this kind of "analysis" sounds like the most banal conventional wisdom. It is so widely accepted, even by many people who think of themselves as seasoned and sophisticated observers of the international scene, that it is hardly worth discussing.

Mead notes that the power of pro-Israel interest groups is predicated on how that bond is expressed in a policy sense - but only when the goal is being pursued with the support of the general public.

"The Jews" do not run America, and they do not run American foreign policy in the Middle East. Recent Pew polls found that Americans sympathize more with the Israeli cause than with the Palestinian one by a margin of 49 percent to 12 percent, and they have consistently favored a "pro-Israel" foreign policy. When the House and the Senate overwhelming endorse pro-Israel resolutions, and when they tell presidents that they can't cut Israel's aid, those politicians are responding to the will of their constituents. Over time, and especially since 9/11, American public opinion has become significantly more pro-Israel....

The reality is that the "Israel lobby" is extremely powerful when its goals accord with non-Jewish American public opinion, but it runs out of steam when it goes against that opinion. It is irresistible when its demands accord with the general disposition of non-Jewish Americans to support the Jewish state; it immediately becomes feeble if it takes up an issue (like a pardon for Pollard) that this public opinion dislikes.

If American Jews actually controlled American policy in the Middle East, it's likely that our policies would be much more dovish and much more nuanced. American Jews by and large are more liberal than the general public on almost every issue, and that emphatically includes the Middle East. While there are some prominent Jewish hawks, there are many more prominent Jewish doves. Barack Obama received far more electoral and financial support from Jewish donors than Mitt Romney in 2012, just as he received far more financial and electoral support than John McCain in 2008.

The American public has demonstrated their preference for the policy positions of their leaders, including Obama, through democratic elections. And in the US, as in Australia, democratic government that does not reflect the will of its electorate is summarily voted out of office.

Mead then takes on the fallback position of the "lobby" conspiracy theorists - that the American public may back Israel, but that is only because the "lobby" controls the media:

Some are ready to concede this point but think they can still attribute American policy to those cunning and all-powerful Jews. Their answer is "the media." American public opinion supports Israel because the clueless and idiotic Americans-so much less sophisticated, so much more poorly educated, so much less rational in their thinking than the enlightened publics of Egypt, Pakistan, Russia, Venezuela, Iran, and Argentina, where a vigilant populace is alert to the insidious plots of the Jews-are fooled by the "Jewish media" into backing the Jewish state.

Once again, this approach betrays a weird combination of anti-Semitic assumptions about Jewish power and cohesion with profound ignorance about American life. The producers of mainstream media coverage in the United States are much closer in their editorial view to what we might call the conventional European vision of the conflict than to the right-wing Israeli view. Ask most correspondents and editors in the media for their private views of the conflict, and they will tell you pretty much what their colleagues in European media would say. That isn't just true of the working stiffs; generally speaking (with some exceptions at Fox), the upper management of these media outlets is closer to the European than to the Likud view.

But news outlets need eyeballs, and the American public doesn't want to watch harrowing stories of Palestinian suffering, and it tunes out the ?blame Israel' narrative. The public likes Israel, thinks it is a good thing, and rejoices when it does well.

Mead argues that an antisemitic outlook, that does not even remotely reflect reality, warps the perception of who controls the political leadership. And he sets the record straight. The "Jewish lobby" and "Jewish media" do not control the government (though the latter has been pointed to in the US and across the pond as the scapegoat for all misfortunes by Israel's detractors). It may not be as sexy as conspiracy and intrigue, but the truth is that the American public votes with their feet, and their television remotes, and largely gets the policies and media coverage they want.

According to McGeough and his contemporaries, the strings of world super power the US are being pulled by the small regional power Israel, through its lobby in Washington, through the media and through accruing Jewish votes for pro-Israel candidates. It is the sort of rhetoric that might be expected from Press TV, or al Jazeera, but it does not belong in mainstream media organisations like Fairfax and the ABC.

The reality of US/Israel relations is far more collaborative and interactive. As Obama noted last week, "innovation is just as important to the relationship between the U.S. and Israel as our security cooperation."

In the Wall Street Journal, Eisenstadt and Pollock agreed that Israeli researchers, scientists, engineers, entrepreneurs and others are helping create US sustainability and security at home and abroad:

"Why did President Obama visit Israel this week, on the first foreign trip of his second term? The U.S. and Israel share democratic values, of course, and there were pressing issues to discuss publicly and privately, including peace with the Palestinians, the civil war in Syria, and Iran's march to nuclear-weapons capability. But there is an additional consideration that is too rarely emphasized: Israel is helping the U.S. meet the economic, environmental and non-military security challenges of the future," they wrote.

The U.S.-Israel relationship isn't symmetrical, as the U.S. provides Israel with indispensable diplomatic and military assistance. But it is a two-way street.

The concerning element of the Israel-as-puppet-master argument is that while it may serve the narrow world view of those like McGeough, it requires a deliberate and willful ignorance of the wide-ranging interactive relationship enjoyed by Israel and the United States, which is clear to see.

Bookmark/Search this post with:


Source: http://www.rslissak.com/content/obama-israel-and-jewish-lobby-talia-katz

optimal Samantha Steele Espn goog Sylvia Kristel st louis cardinals Steelers Schedule tory burch

Accenture acquires ChangeTrack for analytics-based change ...

Thursday, April 4, 2013 by Helena Schwenk

This week Accenture quietly announced its acquisition of Australian predictive analytics service vendor ChangeTrack Research Pty Ltd, for an undisclosed amount.

The company offers a methodology and tool ? called ChangeTracking ? which helps organisations monitor, measure and optimise large scale change management programs, for example where an organisation is undergoing M&A activity, a company-wide ERP or CRM program, or a restructuring exercise. Initiatives of this nature tend to involve managing a complex array of factors and dimensions, including people, technology and processes that need to be continuously aligned and managed; so it?s no surprise that projects often go off track and don?t deliver the business outcome expected. ChangeTrack?s technology aims to address this challenge by providing more rigour and discipline to the measurement process surrounding a program, so managers can pick up on early warn signs and identify where action is needed while change is actually taking place, rather than doing this after the fact (as is often the case).

The notion underlying the offering is that change is not a random set of events, but is in fact a series of very predictable paths that an organisation can take depending on what decisions are made. At the heart of the ChangeTracking tool is a database comprising responses collected from over 600,000 people across more than 300 change programs ? both those that have been successful and others less so. Using the insight and knowledge accumulated over the years, and by capturing survey-based performance information from the client, the tool is able to statistically analyse data ? using its patented mathematical algorithms ? and identify patterns and critical success factors to highlight what is normal and not normal in different types of change programs at different stages. This then forms the basis of an action plan used to help put a program back on track.

ChangeTrack?s methodology and offering has attracted a pretty impressive client list too, including BP, Nike, 3M, LloydsTSB, and Shell. Similarly it has worked with a number of large global consulting firms, including Accenture, with whom it worked as part of product development to help the company understand how consultants plan and implement change in their client organisations. Having a productive working relationship has obviously been an influential factor in Accenture?s decision to key to acquire the company. The consulting firm is expected to use its new purchase to complement its own set of methods, tools and capabilities for measuring and managing change programs. Longer term, however, we can also envisage the tool and its predictive analytics capabilities being used across a wider range of industries and geographies. The other benefit of being own by one of the largest global consulting firms is that the more clients that use the tool, the more data can be collected and analysed, and the better the tool can get at identifying issues and recommending corrective action ? so all in all we see this as a good thing for ChangeTracker and its customers and prospects.

Posted in Analytics, Information Management

Source: http://www.mwdadvisors.com/blog/2013/04/accenture-acquires-changetrack-for-analytics-based-change-management.html

csco big bend national park leon russell meredith vieira prop 8 larry bird maria menounos